| Abstract | Danazol has recently been reported to be an effective mode of treatment for patients with refractory immune thrombocytopenic purpura. Following a 3 month trial of danazol, only one of 10 patients experienced a sustained increase in platelet counts and two other patients had a transient improvement. While the drug was well tolerated, it does not appear to be particularly helpful in the management of these patients. |
| Authors | B A McVerry, M Auger, A J Bellingham |
| Journal | British journal of haematology
(Br J Haematol)
Vol. 61
Issue 1
Pg. 145-8
(Sep 1985)
ISSN: 0007-1048 ENGLAND |
| PMID | 4052322
(Publication Type: Journal Article)
|
| Chemical References |
|
| Topics |
- Adult
- Aged
- Autoimmune Diseases
(blood, drug therapy)
- Chronic Disease
- Danazol
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Platelet Count
- Pregnadienes
(therapeutic use)
- Purpura, Thrombocytopenic
(blood, drug therapy)
|
